Artificial intelligence
More and more companies are turning to artificial intelligence for drug safety prediction, but as with any new application of AI, experts urge caution.
High multiplexed patient-centric assays could reduce patient burden
New platforms are emerging to help biopharma companies fill their human studies more efficiently, but barriers remain to their successful implementation.
A Discussion with IQVIA’s Michelle Gyzen Sr. Director, Regulatory Affairs and Drug Development Solutions
AI and machine learning could transform drug discovery, but first, practitioners must overcome ethical challenges en route to medicines for all.
Google and Microsoft are already making inroads into drug development, but smaller biotechs focused on AI may end up leading the charge.
PRESS RELEASES